ABIOGEN PHARMA S.p.A
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
ABIOGEN PHARMA S.p.A - overview
Established
1997
Location
Pisa, Ospedaletto, Italy
Primary Industry
Pharmaceuticals
About
Based in Italy, ABIOGEN PHARMA S. p. A operates in the pharmaceutical sector, focusing on the development and manufacturing of various medical products, including pharmaceuticals and dietary supplements. ABIOGEN PHARMA S.
p. A specializes in pharmaceuticals and medical devices. Founded in 1997 and headquartered in Pisa, Italy, the company has maintained a consistent focus on healthcare solutions. The founder's history is not detailed in available information.
Abiogen Pharma specializes in the development and manufacturing of pharmaceutical products, medical devices, dietary supplements, and special medical foods. The company focuses on therapeutic areas such as bone metabolism, Vitamin D deficiency, pain management, viscosupplementation, dermatology, respiratory health, and diabetology. Their product offerings are designed to address the medical needs of healthcare professionals and their patients, providing innovative solutions that enhance treatment efficacy and patient outcomes. Abiogen Pharma markets its products in over 40 countries, ensuring a significant international presence in key regions across Europe, Latin America, and Asia.
Their customer base includes healthcare providers, hospitals, pharmacies, and direct consumers seeking effective medical solutions. Abiogen Pharma reported a revenue of EUR 177,757,860. 20 for the year 2023 and an EBITDA of EUR 57,153,484. 70 for the same year.
The company engages in B2B transactions with healthcare providers and distributors, ensuring that its pharmaceutical and medical products reach the end users effectively. Sales are facilitated through partnerships with hospitals and clinics, as well as direct sales to pharmacies and healthcare practitioners. This distribution model allows Abiogen Pharma to maintain a consistent revenue stream through bulk sales and ongoing relationships with healthcare entities. Their flagship product lines, which cater to specific therapeutic areas, contribute significantly to their financial performance and ongoing growth in the competitive pharmaceutical landscape.
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Healthcare, Pharmaceutical Research & Development
Website
www.abiogen.it
Verticals
Manufacturing
Total Amount Raised
Subscriber access only
ABIOGEN PHARMA S.p.A - timeline of key events
ABIOGEN PHARMA S.p.A - financials
| Fiscal Year Ended | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 103,622,214 | 117,269,049 | 131,069,659 | 151,901,876 | 168,440,577 | 183,618,443 | 183,393,090 | 172,138,134 | 190,649,842 | - | - | - |
| % Revenue Growth (YoY) | - | 13.2% | 11.8% | 15.9% | 10.9% | 9.0% | (0.1%) | (6.1%) | 10.8% | - | - | - |
| EBITDA (USD) | 35,153,886 | 44,212,248 | 57,188,766 | 71,931,578 | 80,005,250 | 85,713,222 | 78,351,867 | 75,274,721 | 82,846,074 | - | - | - |
| Operating Income (USD) | 30,334,073 | 39,289,925 | 52,050,470 | 66,947,398 | 74,712,680 | 80,863,407 | 72,965,511 | 69,716,387 | 76,250,412 | - | - | - |
| Operating Margin | 29.3% | 33.5% | 39.7% | 44.1% | 44.4% | 44.0% | 39.8% | 40.5% | 40.0% | - | - | - |
| % EBITDA Margin | 33.9% | 37.7% | 43.6% | 47.4% | 47.5% | 46.7% | 42.7% | 43.7% | 43.5% | - | - | - |
| NET Income (USD) | 18,309,913 | 25,022,978 | 34,198,426 | 44,233,414 | 52,620,214 | 56,791,638 | 50,969,442 | 59,524,581 | 54,154,274 | - | - | - |
| % Net Margin | 17.7% | 21.3% | 26.1% | 29.1% | 31.2% | 30.9% | 27.8% | 34.6% | 28.4% | - | - | - |
ABIOGEN PHARMA S.p.A - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Sale | Completed | EffRx Pharmaceuticals SA | - |
Displaying 1 - 1 of 1
ABIOGEN PHARMA S.p.A - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.